DALLAS, April 11, 2014 /PRNewswire/ --
The "Tissue Diagnostics Market by Technology (Immunohistochemistry, in Situ Hybridization, Digital pathology & Workflow, Special Staining), Disease (Breast Cancer, Gastric Cancer, Lymphoma, Prostate Cancer, Non Small Cell Lung Cancer and Others), Product (Instruments and Consumables), End-Users (Hospitals, Pharmaceutical companies, Research Laboratories, Contract Research Organizations and Others) & by Region (The Americas, Europe, BRIC, Japan & RoW) - Trends & Forecast to 2018", published by MarketsandMarkets, the global tissue diagnostics market is expected to grow at a CAGR of close to 6.97% between 2013 and 2018, to reach $3,924.01 Million by 2018.
Browse 93 market data tables and 25 figures spread through 320 pages and in-depth TOC on "Tissue Diagnostics Market"
Early buyers will receive 10% customization on this report.
The report segments this market by technology, disease, product, end user, and geography. The technology segments included in this report are immunohistochemistry (IHC), in situ hybridization (ISH), digital pathology, and special staining. Of these, the IHC technology segment commanded the largest share of the global Tissue Diagnostics Market in 2013 and is also poised to grow at the highest CAGR between 2013 and 2018. The use of IHC products as companion diagnostics in personalized medicine and increasing incidences of cancer worldwide are the primary growth drivers of this technology segment.
The disease segments included in this report are breast cancer, gastric cancer, lymphoma, prostate cancer, non-small-cell lung cancer (NSCLC), and other disease segments. The breast cancer disease segment commanded the largest share of the global Tissue Diagnostics Market in 2013 and is also poised to grow at the highest CAGR between 2013 and 2018. Breast cancer is the most common form of cancer in women. Nearly 1.7 million new breast cancer cases were diagnosed in 2012. This accounted for 12% of all new cancer cases and 25% of all cancers in women in that year. Alcohol consumption has been linked to post-menopausal breast cancer in women. Lifestyle changes and a rapidly aging population have compounded the effect and have led to increasing incidences of cancer.
The end-user segments included in this report are hospitals, pharmaceutical companies, research laboratories, contract research organizations, and other end users like reference laboratories. Of these, the hospital end-user segment commanded the largest share of the global Tissue Diagnostics Market in 2013, while the research laboratories end-user segment is poised to grow at the highest CAGR between 2013 and 2018. Tissue diagnostics finds primary application for diagnosis of cancer, and its usage for research application by academic and research organization remains low. With the increasing global incidence of cancer, the usage of tissue diagnostics products is also expected to increase.
Based on geography, the global Tissue Diagnostics Market is segmented into the Americas, Europe, BRIC, Japan, and the Rest of the World (RoW). The Americas is further divided into regional segments, such as U.S., Canada, Mexico, Chile, and the Rest of the Americas. The Europe segment is further divided into the regional segments of Germany, France, Italy, Spain, the U.K., and the Rest of Europe. The BRIC segment includes the regional segments of Brazil, Russia, India, and China.
Tissues diagnostics is used to determine the stage, prognosis, and treatment course of cancer. According to the estimates of the International Agency for Research on Cancer (ICRA) and World Health Organization (WHO), 19.3 million new cancer cases are expected to be diagnosed per year by 2025. Growing incidences of cancer will be the most important growth driver for this market for the forecast period between 2013 and 2018. Furthermore, advanced age is considered to be an important risk factor for cancer. The rapidly aging global population will further drive the demand for tissue diagnostics.
The major players in the Tissue Diagnostics Market are Agilent Technologies (U.S.), Abbott Laboratories (U.S.), Bio SB (U.S.), Biogenex Laboratories (U.S.), Cell Signaling Technology (U.S.), Danaher Corporation (U.S.), Life Technologies (U.S.), Roche Diagnostics (Switzerland), Sigma-Aldrich (U.S.), and Thermo Fisher Scientific (U.S.).
Browse related reports
In Vitro Diagnostic (IVD) Market [Instruments, Reagents & Data Management Systems] [Technique (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Haematology) & Applications (Diabetes, Infectious Diseases, Cancer & Cardiology)] Systems, End Users] - Forecast To 2017
Immunoassay Market [Technology (Enzyme, Fluorescent, Chemiluminescence, Radioimmunoassay), Analyzers & Reagents, Applications (Infectious Diseases, Cancer, Endocrinology, Cardiology), End Users (Hospitals, Laboratory, Academics)] - Global Forecast to 2018
MarketsandMarkets is a global market research and consulting company based in the U.S. We publish strategically analyzed market research reports and serve as a business intelligence partner to Fortune 500 companies across the world.
MarketsandMarkets also provides multi-client reports, company profiles, databases, and custom research services. MarketsandMarkets covers thirteen industry verticals; including advanced materials, automotives and transportation, banking and financial services, biotechnology, healthcare information technology, chemicals, consumer goods, telecommunications and IT, energy and power, food and beverages, industrial automation, medical devices, pharmaceuticals, agriculture industry, semiconductor and electronics, aerospace & defense.
We at MarketsandMarkets are inspired to help our clients grow by providing apt business insight with our huge market intelligence repository.
North - Dominion Plaza
17304 Preston Road
Suite 800, Dallas, TX 75252
Email: [email protected]
Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets